Should Dividend Investors Eject Abbott Laboratories Stock?

By Dave Williamson – Jul 2, 2014 at 6:12PM

NYSE: ABT

Abbott Laboratories

Market Cap

$187B

Today's Change

(0.63%) $0.67

Current Price

$107.53

Price as of April 26, 2024, 4:00 p.m. ET

World Cup fever spreads to dividend stock AbbVie

Dividend aristocrat Abbott Labs (ABT 0.63%) has has a long history of rewarding income investors, but after its transformation, is it still one of the sector's top dividend stocks?

In this video, Motley Fool health-care analyst David Williamson will be grading well-known dividend stocks using a World Cup-inspired grading system: a yellow card is a warning for investors, a red card is an ejection, and a "goal" happens if the stock looks like a winner.

Watch and find out the strengths and weaknesses of Abbott Labs, and whether investors should eject it.

David Williamson owns shares of Abbott Laboratories and AbbVie. The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.